Cargando…
Effects of Implementation and Enforcement Differences in Prescription Drug Monitoring Programs in 3 States: Connecticut, Kentucky, and Wisconsin
BACKGROUND AND AIMS: Prescription Drug Monitoring Programs (PDMPs) were designed to curb opioid misuse and diversion by tracking scheduled medications prescribed by medical providers and dispensed by pharmacies. The effects of PDMPs on opioid prescription, misuse and overdose rates have been mixed d...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8013627/ https://www.ncbi.nlm.nih.gov/pubmed/33854323 http://dx.doi.org/10.1177/1178221821992349 |
_version_ | 1783673501998120960 |
---|---|
author | Dickson-Gomez, Julia Christenson, Erika Weeks, Margaret Galletly, Carol Wogen, Jennifer Spector, Antoinette McDonald, Madelyn Ohlrich, Jessica |
author_facet | Dickson-Gomez, Julia Christenson, Erika Weeks, Margaret Galletly, Carol Wogen, Jennifer Spector, Antoinette McDonald, Madelyn Ohlrich, Jessica |
author_sort | Dickson-Gomez, Julia |
collection | PubMed |
description | BACKGROUND AND AIMS: Prescription Drug Monitoring Programs (PDMPs) were designed to curb opioid misuse and diversion by tracking scheduled medications prescribed by medical providers and dispensed by pharmacies. The effects of PDMPs on opioid prescription, misuse and overdose rates have been mixed due in part to variability in states’ PDMPs and difficulties measuring this complexity, and a lack of attention to implementation and enforcement of PDMP components. The current study uses qualitative interviews with key informants from 3 states with different PDMPs, Connecticut, Kentucky and Wisconsin to explore differences in the characteristics of the PDMPs in each state; how they are implemented, monitored and enforced; and unintended negative consequences of these programs. METHODS: We conducted in-depth interviews with key informants from each state representing the following sectors: PDMP and pain clinic regulation agencies, Medicaid programs, state licensing boards, pharmacies, emergency medicine departments, pain management clinics, first responders, drug courts, drug treatment programs, medication assisted treatment (MAT) providers, and harm reduction organizations. Interview guides explored participants’ experiences with and opinions of PDMPs according to their roles. Data analysis was conducted using a collaborative, constant comparison method. RESULTS: While all 3 states had mandated registration and reporting requirements, the states differed in the implementation and enforcement of these and the extent to which provider prescribing was monitored. These, in turn, influenced how medical providers perceived the PDMP and changed how providers prescribed opioids. Unintended consequences of state PDMPs included under-prescribing for pain and “dumping” patients who were long term users of opioids or who had developed opioid use disorders and may explain the increase in illicit heroin or opioid use. CONCLUSION: State PDMPs with similar mandates may differ greatly in implementation and enforcement. These differences are important to consider when determining the effects of PDMPs on opioid misuse and overdose. |
format | Online Article Text |
id | pubmed-8013627 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-80136272021-04-13 Effects of Implementation and Enforcement Differences in Prescription Drug Monitoring Programs in 3 States: Connecticut, Kentucky, and Wisconsin Dickson-Gomez, Julia Christenson, Erika Weeks, Margaret Galletly, Carol Wogen, Jennifer Spector, Antoinette McDonald, Madelyn Ohlrich, Jessica Subst Abuse Original Research BACKGROUND AND AIMS: Prescription Drug Monitoring Programs (PDMPs) were designed to curb opioid misuse and diversion by tracking scheduled medications prescribed by medical providers and dispensed by pharmacies. The effects of PDMPs on opioid prescription, misuse and overdose rates have been mixed due in part to variability in states’ PDMPs and difficulties measuring this complexity, and a lack of attention to implementation and enforcement of PDMP components. The current study uses qualitative interviews with key informants from 3 states with different PDMPs, Connecticut, Kentucky and Wisconsin to explore differences in the characteristics of the PDMPs in each state; how they are implemented, monitored and enforced; and unintended negative consequences of these programs. METHODS: We conducted in-depth interviews with key informants from each state representing the following sectors: PDMP and pain clinic regulation agencies, Medicaid programs, state licensing boards, pharmacies, emergency medicine departments, pain management clinics, first responders, drug courts, drug treatment programs, medication assisted treatment (MAT) providers, and harm reduction organizations. Interview guides explored participants’ experiences with and opinions of PDMPs according to their roles. Data analysis was conducted using a collaborative, constant comparison method. RESULTS: While all 3 states had mandated registration and reporting requirements, the states differed in the implementation and enforcement of these and the extent to which provider prescribing was monitored. These, in turn, influenced how medical providers perceived the PDMP and changed how providers prescribed opioids. Unintended consequences of state PDMPs included under-prescribing for pain and “dumping” patients who were long term users of opioids or who had developed opioid use disorders and may explain the increase in illicit heroin or opioid use. CONCLUSION: State PDMPs with similar mandates may differ greatly in implementation and enforcement. These differences are important to consider when determining the effects of PDMPs on opioid misuse and overdose. SAGE Publications 2021-03-25 /pmc/articles/PMC8013627/ /pubmed/33854323 http://dx.doi.org/10.1177/1178221821992349 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Dickson-Gomez, Julia Christenson, Erika Weeks, Margaret Galletly, Carol Wogen, Jennifer Spector, Antoinette McDonald, Madelyn Ohlrich, Jessica Effects of Implementation and Enforcement Differences in Prescription Drug Monitoring Programs in 3 States: Connecticut, Kentucky, and Wisconsin |
title | Effects of Implementation and Enforcement Differences in Prescription Drug Monitoring Programs in 3 States: Connecticut, Kentucky, and Wisconsin |
title_full | Effects of Implementation and Enforcement Differences in Prescription Drug Monitoring Programs in 3 States: Connecticut, Kentucky, and Wisconsin |
title_fullStr | Effects of Implementation and Enforcement Differences in Prescription Drug Monitoring Programs in 3 States: Connecticut, Kentucky, and Wisconsin |
title_full_unstemmed | Effects of Implementation and Enforcement Differences in Prescription Drug Monitoring Programs in 3 States: Connecticut, Kentucky, and Wisconsin |
title_short | Effects of Implementation and Enforcement Differences in Prescription Drug Monitoring Programs in 3 States: Connecticut, Kentucky, and Wisconsin |
title_sort | effects of implementation and enforcement differences in prescription drug monitoring programs in 3 states: connecticut, kentucky, and wisconsin |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8013627/ https://www.ncbi.nlm.nih.gov/pubmed/33854323 http://dx.doi.org/10.1177/1178221821992349 |
work_keys_str_mv | AT dicksongomezjulia effectsofimplementationandenforcementdifferencesinprescriptiondrugmonitoringprogramsin3statesconnecticutkentuckyandwisconsin AT christensonerika effectsofimplementationandenforcementdifferencesinprescriptiondrugmonitoringprogramsin3statesconnecticutkentuckyandwisconsin AT weeksmargaret effectsofimplementationandenforcementdifferencesinprescriptiondrugmonitoringprogramsin3statesconnecticutkentuckyandwisconsin AT galletlycarol effectsofimplementationandenforcementdifferencesinprescriptiondrugmonitoringprogramsin3statesconnecticutkentuckyandwisconsin AT wogenjennifer effectsofimplementationandenforcementdifferencesinprescriptiondrugmonitoringprogramsin3statesconnecticutkentuckyandwisconsin AT spectorantoinette effectsofimplementationandenforcementdifferencesinprescriptiondrugmonitoringprogramsin3statesconnecticutkentuckyandwisconsin AT mcdonaldmadelyn effectsofimplementationandenforcementdifferencesinprescriptiondrugmonitoringprogramsin3statesconnecticutkentuckyandwisconsin AT ohlrichjessica effectsofimplementationandenforcementdifferencesinprescriptiondrugmonitoringprogramsin3statesconnecticutkentuckyandwisconsin |